In rare cases, allergic or hypersensitivity reactions to tirzepatide could theoretically produce respiratory symptoms, including dyspnea, though such reactions are uncommon
Subsequent to the approval of exenatide, additional GLP-1 RAs have been FDA-approved, with differences across agents in indication for use (eg, pediatrics), route and/or intervals of administration, pharmacology, efficacy, and tolerability
Monitorare il bilancio dei fluidi e gli elettroliti
Metabolism 164:156113 [DOI] [PubMed] [Google Scholar] 13.Linge J, Birkenfeld AL, Neeland IJ (2024) Muscle mass and Glucagon-Like Peptide-1 receptor agonists: adaptive or maladaptive response to weight loss
But not all peptides have regulatory approval as they lack the necessary human safety and efficacy data